Skip to content
Est. 1998 proudly celebrating our 27th year of championing American business
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Lakewood-Amedex Biotherapeutics Inc.

  • UNIVERSITY PARK, Florida
  • Public · NASDAQ: LABT
$9.6MMarket cap
-$923.3KNet income
LABTNASDAQ
2026IPO

About Lakewood-Amedex Biotherapeutics Inc.

Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Net income
-$923.3K
Total assets
$196.3K
Market cap
$9.6M

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: LABT

15-minute delayed · data by Polygon.io

Market cap
$9.6M
Open
Day range
Prev close
Volume
IPO date
Apr 23, 2026

Market data by Polygon.io · prices are 15-minute delayed

No reviews yet. Be the first to review Lakewood-Amedex Biotherapeutics Inc..

Write a review
Explore

Similar companies

Browse all →